A Single Center Phase II Study of Continuous Infusion of Low-dose 5- fluorouracil for Heavily Pretreated Patients With Metastatic Colorectal Cancer

Author(s): Hong-tao Chen, Yi-feng Liao, Mei Xiao, Lin Ma, Hong-Yu Zhang.

Journal Name: Clinical Cancer Drugs

Volume 2 , Issue 2 , 2015

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Objective: Many patients with metastatic colorectal cancer (MCRC) cannot afford the targeted therapy in China. There is no standard treatment when these patients whose tumors relapsed following the first- and second- line chemotherapy. The goal of the present study is to evaluate the efficacy and safety of continuous intravenous infusion (CIV) of low-dose 5-fluorouracil5-FUfor heavily pretreated patients with MCRC. Methods: Twenty-three heavily pretreated patients with MCRC received 5-FU 200 mg/m2 per day as CIV for more than 30 days. Efficacy and safety was evaluated after one cycle of chemotherapy. Results: No patient achieved complete response (CR), 2 patients partial response (PR), 8 patients stable disease (SD), and 13 patients progression disease (PD). Response rate (RR) was 8.7%, disease control rateCR+PR+SD was 43.5%Toxicity was mild. Conclusion: This study showed that continuous venous infusion of low-dose 5-fluorouracil was moderately active and well tolerated in heavily pretreated patients with MCRC.

Keywords: Low-dose 5-fluorouracil, continuous intravenous infusion, metastatic colorectal cancer.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 2
ISSUE: 2
Year: 2015
Page: [87 - 90]
Pages: 4
DOI: 10.2174/2212697X02666151026215656

Article Metrics

PDF: 15
HTML: 1